Replies to post #182314 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I think they did not desire a price surge from ASCO, and they certainly put a sock in pps by witholding timeline guidance as to event rate sought. Ok. Have a good summer. All we have at this point indirectly is the NICE timeline. Good luck to patients.

[sentiment_stocks]

What we should all be asking is who exactly is on this new SAB that now has the power to extend this companies trial for as long as they want.

Dr. Mac Cheever
Dr. Alfredo Quinones-Hinojosa
Dr. Jerome Galon
Dr. Samir N. Khleif
Dr. John Smyth

It seems that 3 years survival data is not considered important enough to unblind and the company has now decided to wait for as many patients to event.

All patients have not been in the trial for 3 years - they will have been in the trial 3 years from surgery in August and 3 years from enrollment in November. So if they do consider 3 years to be an important time event, they have certainly not reached it yet, although I wish very much they had.

[Pablosrv]

Where did you get that?

[hankmanhub]

What rumor? I haven't seen anything like that on this BB. Is this IMHO as well?

[marzan]

The trial was designed and ran to hit the end points 248 PFS and 233 OS. These end points should show I guess 4 months or so advantage from the placebo arm. If unblinded today, the advantage could run into much higher. So, we may not be surprised if FDA steps in and grants some kind of approval.